Grupo Aval Acciones y Valores S.A (AVAL) News
Market Cap: $3.14B
Avg Volume: 153.30K
Industry: Banks - Regional
Sector: Financial Services
Grupo Aval's Q4: Valuation Expanded Significantly (Rating Downgrade)
AVAL's stock valuation has expanded due to a rising share price and decreasing book value post-Q4 earnings. The current price-to-book value of 0.86x aligns with the five-year historical average, but its low ROAE of 6% does not justify it. The company's outlook remains attractive due to expected economic growth and lower inflation in 2025, which could increase loan originations.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q4 2024 Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q4 2024 Earnings Conference Call February 19, 2025 9:00 AM ET Company Participants Maria Lorena Gutierrez Botero - Chief Executive Officer Paula Duran - Corporate Vice President of Sustainability and Strategic Projects Camilo Perez Alvarez - Banco de Bogota's Chief Economist Diego Fernando Solano Saravia - Chief Financial Officer Conference Call Participants Brian Flores - Citigroup Nicolas Riva - BofA Securities Carlos Gomez-Lopez - HSBC Daniel Mora - CrediCorp Capital Julian Ausique Chacon - Davivienda Corredores Operator Welcome to Grupo Aval's Fourth Quarter 2024 Consolidated Results Conference Call.
seekingalpha.com
Read More
Grupo Aval: Improving Financials With The Stock Price Not Reacting
Grupo Aval's net income growth is driven by a lower-risk environment due to lower provisions that affected the company in 2023. Fiscal imbalances in LATAM could weigh on AVAL's stock price, but fundamental improvements present near-term opportunities. Despite historical stock declines and trading below book value, Aval shows strong financial recovery and cyclical opportunities, making it a buy.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores SA (AVAL) Q3 2024 Earnings Conference Call Transcript
Grupo Aval Acciones y Valores SA (NYSE:AVAL ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Maria Gutierrez Botero - CEO Paula Duran - Corporate VP of Sustainability and Strategic Projects Camilo Perez - Banco de Bogota's Chief Economist Diego Solano - CFO Conference Call Participants Brian Flores - Citi Daniel Mora - Credicorp Capital Marlon Medina - J.P. Morgan Julian Ausique - Davivienda Operator Welcome to Grupo Aval's Third Quarter 2024 Consolidated Results Conference Call.
seekingalpha.com
Read More
Is Grupo Aval Acciones y Valores (AVAL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
Read More
Profit for Colombia's Grupo Aval jumps six fold in third-quarter
Colombian financial conglomerate Grupo Aval reported on Wednesday a more than six-fold increase in its third-quarter net profit, climbing to 415.7 billion Colombian pesos ($94.18 million).
reuters.com
Read More
Should Value Investors Buy Grupo Aval Acciones y Valores (AVAL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
Read More
Grupo Aval: Still On The Right Track To Recover
Grupo Aval is poised for recovery due to Colombia's improving macroeconomic conditions, interest rate cuts, and a declining inflation rate. The Colombian economy shows signs of recovery with GDP growth, increased domestic demand, and investment, which should benefit Grupo Aval's profitability. Grupo Aval's net interest margin is expected to expand as rate cuts reduce funding costs, with management optimistic about future loan growth.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores SA (AVAL) Q1 2024 Earnings Call Transcript
Grupo Aval Acciones y Valores SA (NYSE:AVAL ) Q1 2024 Earnings Conference Call May 15, 2024 10:00 AM ET Company Participants Maria Lorena Gutierrez Botero – Chief Executive Officer Diego Fernando Solano Saravia – Chief Financial Officer Conference Call Participants Nicolas Riva – Bank of America Julián Ausique – Davivienda Corredores Operator Welcome to Grupo Aval's First Quarter 2024 Consolidated Results Conference Call. My name is Regina and I will be your operator for today's call.
seekingalpha.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2023
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL; BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2023, with the Securities and Exchange Commission (the “SEC”). Grupo Aval's Form 20-F can be accessed by visiting either the SEC's website at www.sec.gov or the Investor Relations section of the Company's website at www.grupoaval.com. In addition, shareho.
businesswire.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q4 2023 Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q4 2023 Results Conference Call March 5, 2024 9:00 AM ET Company Participants Luis Carlos Sarmiento Gutierrez - Chief Executive Officer Diego Fernando Solano Saravia - Chief Financial Officer Conference Call Participants Julián Ausique - Corredores Daniel Mora - Credicorp Capital Alonso Arambaru - BTG Operator Welcome to Grupo Aval's 4Q 2023 Consolidated Results Conference call.
seekingalpha.com
Read More
Colombia's Grupo Aval reports Q4 profit, despite fall in interest income
Colombian financial conglomerate Grupo Aval posted a year-over-year rise in net profit in the fourth quarter, a securities filing showed on Tuesday, as their investment portfolio experienced positive returns in line with positive financial markets performance.
reuters.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q3 2023 Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (AVAL) Q3 2023 Earnings Call Transcript
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q2 2023 Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q2 2023 Results Conference Call August 17, 2023 10:00 AM ET Company Participants Luis Carlos Sarmiento Gutierrez - Chief Executive Officer Diego Fernando Solano Saravia - Chief Financial Officer Conference Call Participants Nicolas Riva - Bank of America Yuri Fernandes - JPMorgan Operator Welcome to Grupo Aval's Second Quarter 2023 Consolidated Results Conference Call.
seekingalpha.com
Read More
Colombia's Grupo Aval cuts 2023 loan forecast after 'exorbitant costs'
Colombian financial conglomerate Grupo Aval on Thursday cut its 2023 loan growth forecast and hiked its cost of risk estimate, a day after it posted a 75% quarterly profit slump as costs of funds rose for its banking subsidiaries.
reuters.com
Read More
Colombia's Grupo Aval posts 75% fall in profit as bank margins fall
Colombian financial conglomerate Grupo Aval reported a 75.4% year-over-year fall in net profit in the second quarter, according to a securities filing on Wednesday, despite a strong boost in interest income.
reuters.com
Read More
Colombian conglomerate Grupo Aval, subsidiary settle charges of violating US law
Colombian conglomerate Grupo Aval and its bank subsidiary will pay over $80 million to settle charges of violating anti-corruption laws, U.S. authorities said on Thursday.
reuters.com
Read More
Colombian Conglomerate Grupo Aval and Its Bank Subsidiary to Pay $40 Million to Settle FCPA Violations
Washington D.C.--(Newsfile Corp. - August 10, 2023) - The Securities and Exchange Commission today charged Colombian conglomerate Grupo Aval Acciones y Valores S.A.
newsfilecorp.com
Read More
Grupo Aval anuncia la presentación de su formulario 20-F para el año finalizado el 31 de diciembre de 2022
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” o la “Compañía”) (NYSE: AVAL; BVC: acciones con voto: GRUPOAVAL, acciones sin voto: PFAVAL) anuncia la presentación de su formulario 20-F para el año finalizado el 31 de diciembre de 2022 ante la Comisión de Valores y Bolsa (“SEC”). Para acceder al formulario 20-F del Grupo Aval, se puede visitar el sitio web de la SEC, www.sec.gov, o la sección Relaciones con los inversores del sitio web de la Compañía, www.grupoaval.com. Además, los accionistas pueden recibir una copia en papel de los estados financieros auditados de la Compañía bajo NIIF presentados en nuestro formulario 20-F, o bien un formulario 20-F de 2022 completo, incluidos los estados financieros auditados de la Compañía bajo NIIF, sin cargo, si solicitan una copia al equipo de relaciones con los inversores. El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.
businesswire.com
Read More
Grupo Aval anuncia apresentação de seu Formulário 20-F para o ano concluído em 31 de dezembro de 2022
BOGOTÁ, Colômbia--(BUSINESS WIRE)--O Grupo Aval Acciones y Valores S.A. ("Grupo Aval" ou a "Empresa") (NYSE: AVAL; BVC: Ações com direito a voto: GRUPOAVAL, Ações sem direito a voto: PFAVAL), anunciou a apresentação de seu Formulário 20-F para o ano concluído em 31 de dezembro de 2022, junto à Comissão de Valores Mobiliários (Securities and Exchange Commission - SEC). O Formulário 20-F do Grupo Aval pode ser acessado ao acessar o site da SEC em www.sec.gov ou na seção de Relações com Investidores do site da Empresa em www.grupoaval.com. Além disto, os acionistas podem receber uma cópia impressa das demonstrações financeiras auditadas da Empresa em IFRS apresentadas em nosso Formulário 20-F, ou um Formulário 20-F 2022 completo, incluindo demonstrações financeiras auditadas em IFRS, gratuitamente, ao solicitar uma cópia à equipe de Relações com Investidores. O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal.
businesswire.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2022
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL; BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2022, with the Securities and Exchange Commission (the “SEC”). Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in our Form 20-F, or a complete 2022 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the investors relations team.
businesswire.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q4 2022 Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q4 2022 Earnings Conference Call March 6, 2023 9:00 AM ET Company Participants Luis Carlos Sarmiento Gutierrez - CEO Diego Fernando Solano Saravia - CFO Conference Call Participants Yuri Fernandes - JPMorgan Juan Recalde - Scotiabank Operator Welcome to Grupo Aval's Fourth Quarter 2022 Consolidated Results Conference Call.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q3 2022 Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q3 2022 Earnings Conference Call November 17, 2022 9:00 AM ET Company Participants Luis Carlos Sarmiento Gutierrez - Chief Executive Officer Diego Fernando Solano Saravia - Chief Financial Officer Conference Call Participants Nicolas Riva - Bank of America Yuri Fernandes - JPMorgan Julian Ausique - Davivienda José Cuenca - Citigroup Daniel Mora - Credicorp Capital Operator Welcome to the Third Quarter 2022 Consolidated Results under IFRS Conference Call.
seekingalpha.com
Read More
Buying Grupo Aval Post Q3 Earnings
Colombia may experience more challenging times in 2023. Shares in Colombian banking companies like Grupo Aval are undervalued.
seekingalpha.com
Read More
7 Penny Stocks That Could Turn $3 Into $30 (or More) by 2027
While these penny stocks to buy do hold significant dangers because of their speculative nature, this market segment can occasionally deliver massive gains. Therefore, if you have your bases covered, it might not be the most terrible idea to have some exposure to high-risk, high-reward endeavors, so long as you're doing it with money you can afford to lose.
investorplace.com
Read More
Grupo Aval Hostage To Macro And Politics Despite Strong Execution
Grupo Aval is a Colombian financial conglomerate with both commercial banking and higher return asset management and real economy exposure. A recent spin-off of its Central American business has left the company more exposed to Colombia, but also to higher return businesses.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q2 2022 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Luis Carlos Sarmiento Gutierrez - Chief Executive Officer Diego Fernando Solano Saravia - Chief Financial Officer Operator Welcome to Grupo Aval Second Quarter 2022 Consolidated Results Conference Call.
seekingalpha.com
Read More
Down 19.3% in 4 Weeks, Here's Why Grupo Aval Acciones y Valores S.A. (AVAL) Looks Ripe for a Turnaround
Grupo Aval Acciones y Valores S.A. (AVAL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
zacks.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q1 2022 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL ) Q1 2022 Earnings Conference Call May 19, 2022 10:00 AM ET Company Participants Luis Carlos Sarmiento Gutierrez - Chief Executive Officer Diego Solano Saravia - Chief Financial Officer Conference Call Participants Nicolas Riva - Bank of America Jason Mollin - Scotiabank Julian Ausique - Davivienda Corredores Alonso Aramburu - BTG Pactual Luis Carlos Sarmiento Gutierrez Good morning and thank you all for joining our First Quarter 2022 Conference Call.
seekingalpha.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2021
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL; BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2021, with the Securities and Exchange Commission (the “SEC”). Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in Form 20-F, or a complete 2021 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the Investors Relations team.
businesswire.com
Read More
Grupo Aval Acciones y Valores S.A (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q4 2021 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Why You Shouldn't Bet Against Grupo Aval Acciones y Valores Stock
Grupo Aval Acciones y Valores has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
zacks.com
Read More
Why Grupo Aval Acciones (AVAL) Could Be a Top Value Stock Pick
Grupo Aval Acciones (AVAL) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
zacks.com
Read More
Down 12.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Grupo Aval Acciones y Valores S.A. (AVAL)
The heavy selling pressure might have exhausted for Grupo Aval Acciones y Valores S.A. (AVAL) as it is technically in oversold territory now.
zacks.com
Read More
Grupo Aval Acciones y Valores S.A (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q3 2021 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Here Is Why Bargain Hunters Would Love Fast-paced Mover Grupo Aval Acciones y Valores S.A. (AVAL)
Grupo Aval Acciones y Valores S.A. (AVAL) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices.
zacks.com
Read More
Why Grupo Aval Acciones (AVAL) is Such a Great Value Stock Pick Right Now
Grupo Aval Acciones (AVAL) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
zacks.com
Read More
Why Grupo Aval Acciones y Valores S.A. (AVAL) Might be Well Poised for a Surge
Grupo Aval Acciones y Valores S.A. (AVAL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com
Read More
Grupo Aval Is A Strong Buy After Massive Earnings Beat
After trimming my exposure to Colombian stocks in February 2020, I've made a big buy this past week. Colombia's economy has decisively turned the corner; foreign investors haven't picked up on it yet.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q2 2021 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutierrez on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Grupo Aval And Grupo Sura: Valuations Currently More Than Compensate For Political Risk
Grupo Aval And Grupo Sura: Valuations Currently More Than Compensate For Political Risk
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutiérrez on Q1 2021 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutiérrez on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Bancolombia Plunges On Economic Woes And Violent Protests, Creating Opportunity
Bancolombia Plunges On Economic Woes And Violent Protests, Creating Opportunity
seekingalpha.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2020
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2020
businesswire.com
Read More
Hedge Funds Are Dumping Grupo Aval Acciones y Valores S.A. (AVAL)
In this article we will analyze whether Grupo Aval Acciones y Valores S.A. (NYSE:AVAL) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. While not all of these picks will be winners, our research shows that these picks historically outperformed the market by double digits annually.
insidermonkey.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutiérrez on Q3 2020 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (AVAL) CEO Luis Carlos Sarmiento Gutiérrez on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com
Read More
Colombia's Declining Oil Industry Could Trigger An Economic Crisis
Colombia's economic outlook is worsening as oil prices soften.
seekingalpha.com
Read More
7 Penny Stocks With a ‘Strong Buy' Rating
With the stock market soaring, it's time to look off the beaten path for attractive opportunities. These seven penny stocks fit the bill.
investorplace.com
Read More
Grupo Aval Looks Attractive Ahead Of An Earnings Recovery As It Absorbs Pandemic Impacts
Although emerging markets indexes have rebounded significantly from their March lows, the disparity in returns this year between different regions of the world is stark.
seekingalpha.com
Read More
Grupo Aval Acciones y Valores S.A. (AVAL) Q2 2020 Results - Earnings Call Transcript
Grupo Aval Acciones y Valores S.A. (NYSE:AVAL) Q2 2020 Earnings Conference Call August 28, 2020 10:00 A.M.
seekingalpha.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2019
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL) (BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2019, with the Securities and Exchange Commission (the “SEC”). Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in Form 20-F, or a complete 2019 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the investors relations team.
businesswire.com
Read More
Comparing GRUPO AVAL ACCI/S (NYSE:AVAL) and Bank of N.T. Butterfield & Son (NYSE:NTB)
GRUPO AVAL ACCI/S (NYSE:AVAL) and Bank of N.T. Butterfield & Son (NYSE:NTB) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Profitability This table compares GRUPO AVAL ACCI/S and Bank of N.T. […]
thelincolnianonline.com
Read More
Luis Carlos Sarmiento Angulo Donates $20 Million USD to Help with the Covid-19 Crisis in Colombia
BOGOTÁ, Colombia--(BUSINESS WIRE)--Luis Carlos Sarmiento Angulo, Founder and Chairman of Grupo Aval (NYSE listed: AVAL), announced a $20 million donation to help alleviate the impact of Covid-19 in Colombia. The Colombian banker’s contribution will be directed towards funding the acquisition of 300,000 diagnostic kits, which have proven critical in helping to identify and stop the spread of the disease, as well as ventilators, among the most crucial medical equipment necessary to treat the respiratory problems that result from the virus. In addition to the medical aid, Sarmiento Angulo announced that a portion of the donation will go towards providing meals for the most vulnerable segments of the population nationwide, which are struggling to deal with economic impact of the quarantine. This donation complements the aid programs that many of his businesses have already announced, including, among others: 1) Credit relief programs for Grupo Aval’s clients, 2) a $300M USD financing line made available by Grupo Aval to help businesses make payroll and preserve employment, and 3) a $5.5M USD donation by Promigas also focused on addressing Colombia’s health and wellness needs in these times of crisis.
businesswire.com
Read More
Earnings Scheduled For March 17, 2020
Companies Reporting Before The Bell The Michaels Companies, Inc. (NASDAQ: MIK ) is estimated to report quarterly earnings at $1.25 per share on revenue of $1.72 billion. Lands' End, Inc. (NASDAQ: LE ) is projected to report quarterly earnings at $0.77 per share on revenue of $547.93 million. Baxter International Inc. (NYSE: BAX ) is expected to report quarterly earnings at $0.86 per share on revenue of $2.86 billion. HD Supply Holdings, Inc. (NASDAQ: HDS ) is estimated to report quarterly earnings at $0.55 per share on revenue of $1.38 billion. Designer Brands Inc. (NYSE: DBI ) is projected to report quarterly loss at $0.06 per share on revenue of $841.63 million. RumbleON, Inc. (NASDAQ: RMBL ) is estimated to report quarterly loss at $0.34 per share on revenue of $150.41 … Full story available on Benzinga.com
benzinga.com
Read More
7 Underappreciated Foreign Dividend Stocks to Buy Now
This is a great time to add the benefits of diversification to your portfolio with some attractive foreign dividend stocks.
investorplace.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2018
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL) (BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F with the Securities and Exchange Commission (the “SEC”), for the year ended December 31, 2018. Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in Form 20-F, or a complete 2018 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the investors relations team.
businesswire.com
Read More
VALBIOTIS : Bilan semestriel et modification des moyens affectés au contrat de liquidité confié à la société PORTZAMPARC
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS (Paris:AVAL) (FR0013254851 – ALVAL / éligible PEA/PME), entreprise française de Recherche & Développement engagée dans l’innovation scientifique, pour la prévention et la lutte contre les maladies métaboliques, présente aujourd’hui le bilan semestriel du contrat de liquidité confié à la société PORTZAMPARC. Au 30 juin 2018, les moyens suivants figuraient au compte de liquidité : Nombre de titres : 17 740 Solde en espèces du compte de liquidité : 40 090.62 euros Il est rappelé que lors de la mise en œuvre, les moyens suivants figuraient au compte de liquidité : Solde en espèces du compte de liquidité : 150 000.00 euros Apport complémentaire de 50 000.00 euros le 26/12/2017 A PROPOS DE VALBIOTIS VALBIOTIS est une entreprise française de Recherche & Développement engagée dans l’innovation scientifique, pour la prévention et la lutte contre les maladies métaboliques. Ses produits sont destinés aux industriels de l’agro-alimentaire, et de l’industrie pharmaceutique. VALBIOTIS intervient notamment pour la prévention du diabète de type 2, de la NASH (stéatohépatite non-alcoolique), de l’obésité et des pathologies cardio-vasculaires. Créée début 2014 à La Rochelle, l’entreprise a noué de nombreux partenariats avec des centres académiques d’excellence en France et à l’étranger, dont notamment l’Université de la Rochelle, le CNRS, et l’Université Clermont Auvergne située à Clermont-Ferrand, où l’entreprise a ouvert un établissement secondaire. Ces accords lui permettent de bénéficier depuis sa création d’un fort effet de levier grâce notamment à des experts et partenaires techniques mobilisés sur ses projets. Membre du réseau « BPI Excellence » et bénéficiant du label BPI « Entreprise Innovante », VALBIOTIS dispose aussi du statut « Jeune Entreprise Innovante » et a obtenu un appui financier important de l’Union Européenne pour ses programmes de recherche via l’obtention de Fonds Européen de Développement Économique Régional (FEDER). Toute l’information sur VALBIOTIS :http://valbiotis.com/ Nom : VALBIOTISCode ISIN : FR0013254851Code Mnémonique : ALVAL
businesswire.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2017
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL) (BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2017, with the Securities and Exchange Commission (the “SEC”). Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in Form 20-F, or a complete 2017 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the investors relations team.
businesswire.com
Read More
VALBIOTIS : Agenda de communication financière 2018
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS (Paris:AVAL) (FR0013254851 – ALVAL / éligible PEA/PME), société spécialisée dans le développement de solutions nutritionnelles innovantes dédiées à la prévention des maladies cardio-métaboliques et à l’accompagnement nutritionnel des patients, présente ses prochains rendez-vous de communication financière pour l’année 2018 : 3 avril : Publication des résultats annuels 2017 (avant Bourse) 5 avril : Conférence Portzamparc MidCap 2018 27-28 juin : Spring European Midcap Event 2018, Paris 3 juillet : Journée Nutrition - SFAF 28 septembre : Publication des résultats du premier semestre 2018 (après Bourse) 8-9 octobre : European Large & Midcap Event Paris 2018 4-5 décembre : Geneva European Midcap Event 2018 Décembre : Biomed Event Paris – Invest Securities Dans le but de renforcer ses liens avec ses actionnaires particuliers et institutionnels, VALBIOTIS a décidé la diffusion régulière d’une Lettre aux Actionnaires, dont le premier numéro a été envoyé par voie postale au mois de février 2018. Une présentation de la Société a également été mise à jour en février 2018. Ces deux documents sont disponibles sur le site web de la Société, au lien suivant : http://valbiotis.com/documentation/ A PROPOS DE VALBIOTIS VALBIOTIS est une société spécialisée dans le développement de solutions nutritionnelles innovantes dédiées à la prévention des maladies cardio-métaboliques et à l’accompagnement nutritionnel des patients. Ses produits sont destinés aux industriels de l’agro-alimentaire, et de l’industrie pharmaceutique. VALBIOTIS intervient notamment pour la prévention du diabète de type 2, de la NASH (stéatohépatite non-alcoolique), de l’obésité et des pathologies cardio-vasculaires. Créée début 2014 à La Rochelle, la Société a noué de nombreux partenariats avec des centres académiques d’excellence en France et à l’étranger, dont notamment l’Université de la Rochelle, le CNRS, et l’Université Clermont Auvergne située à Clermont-Ferrand, où la Société a ouvert un établissement secondaire. Ces accords lui permettent de bénéficier depuis sa création d’un fort effet de levier grâce notamment à des experts et partenaires techniques mobilisés sur ses projets. Membre du réseau « BPI Excellence » et bénéficiant du label BPI « Entreprise Innovante », VALBIOTIS dispose aussi du statut « Jeune Entreprise Innovante » et a obtenu un appui financier important de l’Union Européenne pour ses programmes de recherche via l’obtention de Fonds Européen de Développement Economique Régional (FEDER). Toute l’information sur VALBIOTIS :http://valbiotis.com/ Nom : VALBIOTISCode ISIN : FR0013254851Code Mnémonique : ALVAL
businesswire.com
Read More
VALBIOTIS: Financial Communication Calendar for 2018
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS (Paris:AVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, today presents its financial communication calendar for 2018: April 3, 2018: Publication of 2017 financial statements (pre-market) April 5, 2018: Portzamparc MidCap Conference 2018 June 27-28, 2018: Spring European Midcap Event 2018, Paris July 3, 2018: “Journée Nutrition” - SFAF September 28, 2018: Publication of the Half Year 2018 financial statements(after market) October 8-9, 2018: European Large & Midcap Event Paris 2018 December 4-5, 2018: Geneva European Midcap Event 2018 December: Biomed Event Paris – Invest Securities In order to strengthen its relationships with its shareholders, VALBIOTIS has decided to start editing and circulating a “Letter to the shareholders”, on a regular basis. The first issue was printed and sent by mail in February 2018. A corporate presentation has also been updated in February 2018. Both digital documents are available on the company website, at the following link: http://VALBIOTIS.com/en/documentation/ ABOUT VALBIOTIS VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agri-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These agreements enable it to benefit from a considerable leverage effect since it was set up thanks, in particular, to the experts and technical partners mobilized for these projects. VALBIOTIS is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. VALBIOTIS has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). Find out more about VALBIOTIS:http://VALBIOTIS.com/ Name: VALBIOTISISIN code: FR0013254851Mnemonic Code: ALVAL
businesswire.com
Read More
Metformin + TOTUM-63 Combination: VALBIOTIS Announces First Preclinical Data for Possible Use in Diabetes Real Life Practice
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS (Paris:AVAL) (FR0013254851 – ALVAL / PEA/PME eligible [the PEA-PME scheme is a share savings plan aimed at providing financing aid to SMEs]), a company specialized in the development of innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, today announces initial positive preclinical data on the combination of metformin with TOTUM-63, for possible use in diabetes real life practice. These results were selected and will be presented during the annual congress of the International Diabetes Federation in Abu Dhabi (UAE) on December 5, 2017. Metformin is considered as the first-line standard treatment prescribed for newly diagnosed type 2 diabetic patients. This medication belongs to the class of oral antidiabetic drugs and is used to normalize fasting glycemia by increasing insulin sensitivity and by reducing neoglucogenesis (production of glucose by the liver). > Metformin as a possible combination: an additional asset for the use of VALEDIA® in real life practice While the safety of TOTUM-63 alone has already been proven, VALBIOTIS provides new data for the active ingredient of VALEDIA® in order to supply all the necessary data for patients and healthcare professionals to use this product in real life. Tested in combination with metformin in murine models (C57BL6/J), TOTUM-63 has not demonstrated any risk of hypoglycemia. Furthermore, initial data in these murine models suggest a beneficial potentiating effect of TOTUM-63 on the reduction of insulinemia induced by metformin, in response to an oral glucose tolerance test (Fig. 1). Figure 1: Insulinemic response in murine models during an oral glucose tolerance test (OGTT) after 16 weeks of complementation with metformin, alone or in combination with TOTUM-63 (*p <0.05). OGTT: Oral glucose tolerance testAUC: Area under curveHFD: High-fat diet These favorable initial results pave the way for a clinical trial in type 2 diabetic patients treated with metformin, which will provide all the necessary data for an optimal use of VALEDIA® in current diabetes practice. ABOUT VALBIOTIS VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agri-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand, where the company opened a second office. These agreements enable it to benefit from a considerable leverage effect since it was set up thanks, in particular, to the experts and technical partners mobilized for these projects. VALBIOTIS is a member of the “BPI Excellence” network and received the “Innovative Company” status accorded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). Find out more about VALBIOTIS:http://valbiotis.com/ Name: VALBIOTISISIN code: FR0013254851Mnemonic code: ALVAL
businesswire.com
Read More
Association metformine + TOTUM-63 : VALBIOTIS annonce des premières données précliniques en vue d’une utilisation possible dans la pratique réelle en diabétologie
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS (Paris:AVAL) (FR0013254851 – ALVAL / éligible PEA/PME), société spécialisée dans le développement de solutions nutritionnelles innovantes dédiées à la prévention des maladies cardio-métaboliques et à l’accompagnement nutritionnel des patients, annonce aujourd’hui des premières données précliniques positives sur l’association de la metformine avec TOTUM-63, en vue d’une utilisation possible dans la pratique réelle en diabétologie. Ces résultats ont été sélectionnés et seront présentés lors du congrès annuel de la Fédération Internationale du Diabète à Abu-Dhabi (EAU) le 5 décembre 2017. Toujours prescrit en première intention, la metformine est le standard de traitement du diabète de type 2 chez les patients diabétiques nouvellement diagnostiqués. Ce médicament de la classe des antidiabétiques oraux est utilisé pour normaliser la glycémie à jeun, via l’amélioration de la sensibilité des tissus à l’insuline et la réduction de la néoglucogénèse (production de glucose par le foie). > L’association possible à la metformine : un atout supplémentaire pour l’utilisation de VALEDIA® dans la pratique réelle en diabétologie Alors que la sécurité d’utilisation de TOTUM-63 seul a déjà été démontrée, VALBIOTIS apporte des garanties nouvelles pour le principe actif de VALEDIA®, avec l’objectif de fournir toutes les données nécessaires à l’utilisation de ce produit par les patients et les professionnels de santé, en vie réelle. Testé en association avec la metformine dans des modèles murins (C57BL6/J), TOTUM-63 n’a ainsi pas montré de risque hypoglycémique. En outre, chez les mêmes modèles murins, des premières données suggèrent un effet potentialisateur bénéfique de TOTUM-63 sur la réduction de l’insulinémie induite par la metformine, en réponse à un test oral de tolérance au glucose (fig. 1). Figure 1. Réponse insulinémique chez des modèles murins soumis à un test oral de tolérance au glucose (OGTT), après 16 semaines de complémentation par la metformine, seule ou associée à TOTUM-63 (* p < 0,05). Ces premiers résultats favorables ouvrent la voie à un essai clinique chez les patients diabétiques de type 2 traités par la metformine, qui apportera toutes les données nécessaires à une utilisation optimale de VALEDIA® dans la pratique réelle. A PROPOS DE VALBIOTIS VALBIOTIS est une société spécialisée dans le développement de solutions nutritionnelles innovantes dédiées à la prévention des maladies cardio-métaboliques et à l’accompagnement nutritionnel des patients. Ses produits sont destinés aux industriels de l’agro-alimentaire, et de l’industrie pharmaceutique. VALBIOTIS intervient notamment pour la prévention du diabète de type 2, de la NASH (stéatohépatite non-alcoolique), de l’obésité et des pathologies cardio-vasculaires. Créée début 2014 à La Rochelle, la Société a noué de nombreux partenariats avec des centres académiques d’excellence en France et à l’étranger, dont notamment l’Université de la Rochelle, le CNRS, et l’Université Clermont Auvergne située à Clermont-Ferrand, où la Société a ouvert un établissement secondaire. Ces accords lui permettent de bénéficier depuis sa création d’un fort effet de levier grâce notamment à des experts et partenaires techniques mobilisés sur ses projets. Membre du réseau « BPI Excellence » et bénéficiant du label BPI « Entreprise Innovante », VALBIOTIS dispose aussi du statut « Jeune Entreprise Innovante » et a obtenu un appui financier important de l’Union Européenne pour ses programmes de recherche via l’obtention de Fonds Européen de Développement Economique Régional (FEDER). Toute l’information sur VALBIOTIS :http://valbiotis.com/ Nom : VALBIOTISCode ISIN : FR0013254851Code Mnémonique : ALVAL
businesswire.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2016
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL) (BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2016, with the Securities and Exchange Commission (the “SEC”). Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in Form 20-F, or a complete 2016 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the investors relations team.
businesswire.com
Read More
Grupo Aval Announces the Filing of Its Form 20-F for the Year Ended December 31, 2015
BOGOTÁ, Colombia--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) (NYSE: AVAL; BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL), announces the filing of its Form 20-F for the year ended December 31, 2015, with the Securities and Exchange Commission (the “SEC”). Grupo Aval’s Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the Investor Relations section of the Company’s website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company’s audited financial statements under IFRS presented in Form 20-F, or a complete 2015 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from the investors relations team.
businesswire.com
Read More
Grupo Aval Announces Pricing of Initial Public Offering
BOGOTÁ--(BUSINESS WIRE)--Grupo Aval Acciones y Valores S.A. (“Grupo Aval” or the “Company”) today announced the pricing of its initial public offering of 1,629,629,640 preferred shares, par value Ps 1.00 per share, issued in the form of American Depositary Shares (“ADSs”), at a price of U.S.$13.50 per ADS. Each ADS represents 20 preferred shares of the Company. The ADSs are expected to begin trading on the New York Stock Exchange on September 23, 2014 under the ticker “AVAL.” All of the ADSs are being offered and sold by Grupo Aval. In addition, Grupo Aval has granted the underwriters a 30-day option to purchase up to 12,222,223 additional ADSs to cover over-allotments, representing 244,444,460 preferred shares at the initial public offering price. J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as global coordinators and joint book-running managers for the offering. Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are acting as joint book-running managers for the offering. A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering will be made only by means of a prospectus, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, e-mail: prospectus-ny@ny.email.gs.com ,Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146), or Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, New York, NY 10014, telephone: 866-718-1649, e-mail: prospectus@morganstanley.com. About Grupo Aval Grupo Aval is the largest banking group in Colombia and in Central America, in each case, based on total assets. Grupo Aval provides a comprehensive range of financial services and products ranging from traditional banking services, such as making loans and taking deposits, to pension and severance fund management. Bio Luis Carlos Sarmiento Gutiérrez Luis Carlos Sarmiento Gutiérrez, President of Grupo Aval Shares and Securities S.A. since 2000, with 30 years of professional experience in Colombia and United States (24 years with the Sarmiento Group entities). Chairman of the Board of Directors of the Banco de Bogota since 2004, Corficolombiana since 2006 and BAC Credomatic since 2010. Under the leadership of his father, Mr. Sarmiento Angulo, Luis Carlos Sarmiento Gutiérrez has led the process of internationalization of Grupo Aval, launched in 2010. Under their administration there have been milestones such as the purchase of BAC Credomatic in 2010, the registration of Grupo Aval with the SEC of the United States in 2011, the execution of two bond issuances in international markets in 2012, two issues of shares in the local market, in 2011 and 2013, and the purchase of AFP Horizonte, BBVA Panama and Grupo Financiero Reofrma, all during 2013. Bio Luis Carlos Sarmiento Angulo Luis Carlos Sarmiento Angulo is a civil engineer from the Universidad Nacional de Colombia, where he graduated with honors in 1954 at age 21. His first occupation after graduation was as a contractor of public works. In 1959, he began a long and illustrious career as a real estate developer. Over the last ten years he has also become involved in the construction of office buildings and shopping malls. In total, Mr. Sarmiento Angulo has built more than 6 million square meters. In 1970, he extended his activities into banking. Throughout his life he has founded and / or acquired more than 20 financial institutions. In 1996, he founded Grupo Aval to optimize the management of the financial institutions he controlled. Currently all these acquisitions have been merged into 4 main banks: Bogota, Occidente, Popular and AVVillas. Through Grupo Aval he also controls a pension fund (Porvenir), a merchant bank (Corporación Financiera Colombiana) and a bank in Central America (BAC Credomatic). BAC Credomatic was acquired in 2010 from GE Capital and represented Grupo Aval’s first transformational acquisition internationally. Grupo Aval has approximately 30% market share of the Colombian financial system and is the largest financial conglomerate in Central America. Grupo Aval currently has Assets Under Management of over US$86 billion. From his position as Chairman of the Board of Grupo Aval, a position Mr. Sarmiento Angulo has held since the founding of the company, he controls and directs the operations of Grupo Aval, as well he leads the development and construction of all of the projects in the group. Mr. Sarmiento Angulo is the largest shareholder of Grupo Aval. Mr. Sarmiento Angulo is married to Fanny Gutiérrez de Sarmiento and they have five children and eleven grandchildren.
businesswire.com
Read More